| __timestamp | Catalent, Inc. | Dyne Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1229100000 | 1145000000 |
| Thursday, January 1, 2015 | 1215500000 | 2028000000 |
| Friday, January 1, 2016 | 1260500000 | 2281000000 |
| Sunday, January 1, 2017 | 1420800000 | 2932000000 |
| Monday, January 1, 2018 | 1710800000 | 24000 |
| Tuesday, January 1, 2019 | 1712900000 | 271000 |
| Wednesday, January 1, 2020 | 2111000000 | 700000 |
| Friday, January 1, 2021 | 2646000000 | 1088000 |
| Saturday, January 1, 2022 | 3188000000 | 3345000 |
| Sunday, January 1, 2023 | 3216000000 | 2461000 |
| Monday, January 1, 2024 | 3428000000 |
Cracking the code
In the ever-evolving landscape of the pharmaceutical industry, understanding cost trends is crucial. Catalent, Inc. and Dyne Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Catalent's cost of revenue surged by approximately 179%, reflecting its aggressive expansion and scaling efforts. In 2014, Catalent's cost of revenue was around 1.2 billion, climbing to over 3.2 billion by 2023. Meanwhile, Dyne Therapeutics presents a more volatile picture. After peaking in 2017, its costs plummeted, with a notable dip in 2018 to just 24,000, before stabilizing around 3.3 million in 2022. This fluctuation highlights the challenges faced by emerging biotech firms in managing operational costs. The data for 2024 is incomplete, leaving room for speculation on future trends. This analysis underscores the importance of strategic financial management in the competitive biotech sector.
Cost Insights: Breaking Down Merck & Co., Inc. and Catalent, Inc.'s Expenses
Analyzing Cost of Revenue: Pfizer Inc. and Catalent, Inc.
Cost of Revenue Comparison: Pfizer Inc. vs Dyne Therapeutics, Inc.
Analyzing Cost of Revenue: Regeneron Pharmaceuticals, Inc. and Dyne Therapeutics, Inc.
Cost Insights: Breaking Down BeiGene, Ltd. and Dyne Therapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Insmed Incorporated and Catalent, Inc.'s Expenses
Catalent, Inc. vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Catalent, Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Corcept Therapeutics Incorporated vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Dyne Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs Dyne Therapeutics, Inc.